We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 383

Supreme Court declines to hear Eli Lilly’s “promise of the patent” appeal

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • May 16 2013

The Supreme Court of Canada denied leave to appeal today from the Federal Court of Appeal ("FCA") decision in Eli Lilly Canada Inc v Novopharm Ltd

What goes upmust come down: Viagra patent invalidated by Canadian Supreme Court

  • Drinker Biddle & Reath LLP
  • -
  • Canada
  • -
  • May 13 2013

Pfizer and Teva have been fighting a legal battle over Pfizer's patent for Viagra in Canada. The first shot was fired when Novopharm Limited, now

Supreme Court of Canada denies leave to appeal in PM(NOC) judicial comity case

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • May 9 2013

The Supreme Court of Canada denied leave to appeal today from the Federal Court of Appeal ("FCA") decision in Allergan Inc. et al ats. Apotex Inc

Dispelling the Myriad gene patent harmonization myth

  • Foley & Lardner LLP
  • -
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • -
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

A balancing act: innovation and the regulatory-approval exemption

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

In the pharmaceutical sector, patent systems are concerned with balancing the interests of innovator drug companies, the public and generic

Double-patenting challenges for life sciences companies

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Perhaps more than any other technology field, patentees in the life sciences sector tend to be holders of patent families: collections of patents and

Generic ordered to pay $1.7 million in accounting of profits

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

On March 12, 2013, the Federal Court released its decision in Apotex Inc. v. H. Lundbeck AS, 2013 FC 192. The Court dismissed Apotex's action to

USTR slams Canada over the treatment of pharmaceutical patents

  • Norton Rose Canada LLP
  • -
  • Canada
  • -
  • May 6 2013

On May 1, 2013, the United States Trade Representative (“USTR”) released its annual IP report for 2013. Canada has been placed on the “Watch List"

Mylan Pharmaceuticals ULC v. Pfizer Canada Inc., 2012 FCA 103 - Aricept (donepezil), appeal of NOC case

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 3 2012

The Court of Appeal upheld on Order prohibiting the Minister of Health from issuing a NOC to Mylan for donepezil, a drug for the treatment of Alzheimer's type dementia, until expiry of Pfizer’s ‘808 Patent

Teva Canada Innovation v. Attorney General of Canada

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 8 2013

The Patented Medicine Prices Review Board (the PMPRB) ordered Teva to pay the Crown approximately $2.4 million for selling its product at an

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy